What Плаквенил Treats: Main Uses and Benefits

The medicine is commonly used for managing conditions involving episodic or fluctuating manifestations of systemic autoimmune diseases and, separately, in the context of malaria. It is utilized for the management of Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), and in the context of Malaria.

Therapeutic Domains and Benefits

The medication is used in conditions involving episodic or fluctuating manifestations of systemic autoimmune diseases, notably SLE, RA, and Chronic Discoid Lupus Erythematosus (DLE). It is applied in clinical settings that involve symptoms related to inflammatory or irritative states and is generally relevant for easing symptoms by supporting management of its manifestations over time. This sustained management may assist with maintaining functional stability and contributes to easing the overall symptom load by supporting general well-being during symptomatic phases.

“This treatment is commonly applied to address symptom clusters that may become intense or disruptive, such as persistent joint swelling and stiffness, and symptoms related to inflammatory or irritative states of the skin seen in lupus.”

The medication may assist with contributing to physical comfort and supports the patient during difficult episodes by easing distress. It may also be considered relevant for easing symptoms in pediatric patients with Juvenile Idiopathic Arthritis (JIA). In the infectious disease domain, it is applied in addressing acute attacks of Malaria caused by certain susceptible parasites. When used as malaria prevention (prophylaxis), it may assist with reducing the risk of contracting the symptomatic disease.

---

Quick Fact: Relief for Inflammatory Symptoms

The medication helps manage symptoms related to inflammatory or irritative states, including joint stiffness, swelling, and chronic skin rashes associated with systemic autoimmune disease.

Regulatory References

1. NIH MedlinePlus overview of Hydroxychloroquine uses

The eligibility for using Плаквенил (Hydroxychloroquine Sulfate) is strictly defined by government regulatory agencies based on contraindications and patient-specific conditions.

Populations for Whom Use is Contraindicated

Use of this medicine is prohibited for patients with:

• Known hypersensitivity or allergy to 4-aminoquinoline compounds (including hydroxychloroquine or chloroquine).
• Pre-existing maculopathy or retinal/visual field changes linked to 4-aminoquinoline use.
• Children below 6 years of age. Use for long-term therapy in children may also be contraindicated in some jurisdictions.

Age- and Condition-Based Restrictions

Category	Official Eligibility Restriction/Status
Pediatric Patients	Not recommended for use in children below 6 years of age. Use is not recommended for prophylaxis/treatment in pediatric patients weighing less than approximately 31 kg (due to fixed tablet strength exceeding the recommended dose).
Organ Impairment	Caution is required and dosage adjustment may be necessary for patients with pre-existing hepatic disease or renal insufficiency.
Comorbidities	Use is restricted or requires special caution in patients with psoriasis or porphyria, as the medicine may exacerbate these conditions. Caution is also advised in patients with G-6-PD deficiency.
Pregnancy/Lactation	Pregnancy: Use should be avoided unless the official assessment determines the benefit for the mother outweighs the possible hazard. Lactation: Use is not recommended due to excretion into breast milk.

Interactions with other medicines and products

Official regulatory information for Плаквенил (Hydroxychloroquine) details specific interaction patterns across three main domains: contraindicated combinations, pharmacokinetic interference, and pharmacodynamic risk.

Contraindicated Combinations

Co-administration with agents known to significantly prolong the QT interval, such as Halofantrine, is restricted due to the documented risk of ventricular arrhythmias. Use with drugs known to induce retinal toxicity, such as Tamoxifen, is not recommended due to an increased risk of damage.

Pharmacokinetic Interference

Hydroxychloroquine is documented as an inhibitor of P-glycoprotein (P-gp) and CYP2D6, which can lead to increased plasma concentrations of co-administered substrates, including Digoxin, Cyclosporine, and Metoprolol. Conversely, co-administration with enzyme inducers like Rifampin may reduce the systemic exposure of Hydroxychloroquine. Administration with Cimetidine may increase Hydroxychloroquine exposure.

Pharmacodynamic and Administration Rules

The medicine may enhance the effects of antidiabetic drugs (e.g., Insulin, Metformin), increasing the risk of hypoglycemia. Concomitant use with agents that lower the convulsive threshold may increase the risk of seizures. Additionally, gastrointestinal adsorbents like Antacids or Kaolin must be administered at least 4 hours apart to prevent reduced Hydroxychloroquine absorption. Use with alcohol is cautioned due to an increased risk of hepatotoxicity. In patients with hepatic or renal impairment, the risk of drug accumulation and potential for interactions may be increased due to slower removal.

Intracellular pH Modulation and Pathway Interference

The molecule functions as a weak base, leading to its sequestration and accumulation within naturally acidic intracellular vesicles, primarily lysosomes and endosomes. This process, termed lysosomotropism, causes an elevation in the internal pH of these compartments. The resulting alkaline environment impairs the function of acid-dependent enzymes and disrupts the normal processing of proteins, initiating a cascade that modulates cellular response magnitude.

The mechanism focuses on key signaling components, including Toll-like Receptors (TLR7 and TLR9), whose activation is pH-dependent. Inhibition of TLR signaling suppresses the downstream transcriptional activation of factors like NF-kappaB, leading to reduced production of pro-inflammatory mediators (e.g., cytokines and chemokines). Concurrently, the molecule interferes with the assembly and presentation of antigens via MHC Class II molecules on Antigen-Presenting Cells. This collective molecular interference modifies immune cell communication and defines the resulting systemic physiological modulation of cellular reactivity.

Plaquenil (Hydroxychloroquine Sulfate) is administered by the oral route as a 200 mg film-coated tablet. To support proper administration and gastrointestinal tolerability, the medicine is taken with a meal or a glass of milk. The tablet is to be swallowed whole and is not to be crushed or divided.

The usage pattern and frequency are determined by the condition being managed. For the long-term management of chronic systemic autoimmune diseases, the medicine is typically used on a once-daily schedule, although the total daily amount may be split into two doses. The long-term maintenance dose generally falls within the range of 200 mg to 400 mg per day. A standard guideline for chronic use specifies that the daily dose should not exceed 6.5 mg per kilogram of the patient’s ideal body weight, establishing a specific dosing limit.

In the context of malaria, a distinct, time-bound regimen applies. For prophylaxis, the medicine is taken once weekly, requiring administration to begin two weeks prior to travel and continue for four weeks after leaving the endemic area. Conversely, the treatment of an acute malaria attack involves a higher, multi-dose loading schedule administered over a 48-hour period. The therapeutic effect for chronic conditions is cumulative, and treatment may be discontinued if no clinical improvement is observed within four to six months. Weight-based administration rules apply to pediatric patients, and the 200 mg tablet strength is not recommended for children weighing less than 31 kg.

Research evidence / Overview of studies for Плаквенил

The research on Плаквенил (Hydroxychloroquine) comes primarily from long-term observational studies, clinical trials, and systematic reviews, which inform the regulatory assessment of its use in certain chronic conditions. This summary describes the scope and structure of that research without offering advice or recommendations.

---

Evidence for Use in Systemic Lupus Erythematosus (SLE)

Studies for Systemic Lupus Erythematosus (SLE) focused on long-term patient outcomes, recognizing the chronic nature of the condition. Researchers monitored adult populations with established SLE to measure and report on survival rates and the cumulative accrual of organ damage. Furthermore, randomized controlled trials were conducted to assess outcomes such as the frequency of disease flares, the relationship with cardiovascular risk markers, and the measured need for concurrent corticosteroid therapy.

Research has explored patterns related to disease activity and the incidence of thrombotic events in the observed populations. Research also highlights measured patterns related to total corticosteroid exposure over time in patient groups in the observed cohorts. The evidence is limited in isolating the medicine's specific contribution since research frequently assesses it when used alongside other existing therapies.

---

Evidence for Use in Rheumatoid Arthritis (RA)

Research on Rheumatoid Arthritis (RA) has included both randomized controlled trials (RCTs) and retrospective cohort studies. The RCTs evaluated whether changes occurred in outcomes related to physical discomfort and monitored changes in inflammatory biomarkers such as C-reactive protein (CRP). Observational studies explored long-term associations with overall health, including cardiovascular outcomes, in adults with established RA.

Studies reported how symptoms evolved in the observed populations, noting measurements of joint discomfort and stiffness, alongside changes in functional capacity scores. Evidence quality varies across studies, and research on preventing long-term joint damage has not been consistently confirmed across all later investigations. The medicine is frequently studied as part of combination therapy, which can limit the ability to fully determine its singular contribution.

---

Evidence in Specific Patient Populations

Research has been conducted to evaluate the use of this medicine in specific groups, including pediatric patients with certain classifications of Juvenile Idiopathic Arthritis (JIA). For JIA, studies are often limited to retrospective analyses, usually observing the medicine’s use as an adjunct (add-on) therapy to other treatments for managing inflammatory symptoms. Additionally, research has explored the use of the medicine in pregnant women with SLE, focusing on maternal and fetal outcomes, with findings described in long-term observational settings.

---

What is Still Uncertain About the Research

Evidence gaps and areas of uncertainty remain. Long-term effects on certain physiological parameters are not fully established, particularly when evidence is based only on observational studies. Subgroup findings are uncertain due to limited information for certain populations, such as specific ages or those with certain comorbidities. Its evaluation is often conducted only when it is used as part of combination therapy, making it challenging to isolate the independent contribution of this agent.

Key Studies & References

1. Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension
2. Hydroxychloroquine: MedlinePlus Drug Information (for general indications/malaria context)

Common questions about Плаквенил (FAQ)

---

Q: В чем разница между Плаквенил и другими препаратами от артрита?

A: Official information classifies Plaquenil as both an Antimalarial Agent and a Disease-Modifying Anti-Rheumatic Drug (DMARD). This classification distinguishes it from other arthritis treatments, such as corticosteroids or biologics. It is indicated for treating conditions like Rheumatoid Arthritis and Systemic Lupus Erythematosus, often used as part of a combination therapy.

---

Q: Действие Плаквенил временное или постоянное?

A: Plaquenil is intended for the long-term management of chronic autoimmune diseases. However, regulatory guidelines note that the medicine may be discontinued if no clinical improvement is observed within four to six months of starting treatment.

---

Q: Какова общая информация о безопасности Плаквенил при длительном приеме?

A: Official safety information indicates that the risk of serious adverse effects, particularly retinopathy (eye damage) and cardiomyopathy (heart muscle damage), is associated with the duration of use and the total cumulative dose. Regulatory documents emphasize the importance of regular monitoring of the eyes and heart for long-term users.

---

Q: Чем отличаются перепады настроения от психоза при приеме Плаквенил?

A: Regulatory adverse event reports include both general mood changes and more serious neuropsychiatric reactions. These severe reactions, which are uncommon, may include psychosis, suicidal thoughts, and other unusual behavioral changes.

---

Q: Что делать, если при приеме Плаквенил возникает тошнота?

A: Nausea and abdominal pain are listed as common side effects. To help minimize these gastrointestinal symptoms, regulatory guidelines recommend administration of the medicine with a meal or a glass of milk.

---

Q: Как распознать начало серьезных побочных эффектов?

A: The occurrence of serious side effects necessitates immediate medical consultation. Regulatory documents state that symptoms such as sudden, unexplained vision changes or signs of cardiac issues (e.g., fast heart rate or fainting) warrant consultation with a healthcare professional.

---

Q: В каких случаях нужно прекратить прием Плаквенил из-за побочных эффектов?

A: The product labeling requires discontinuation of the medicine if there are confirmed signs of serious complications. These include signs of ocular toxicity (retinal changes), suspected cardiomyopathy (heart damage), or identification of serious hematological disorders (blood abnormalities).

---

Q: Какова обычная продолжительность курса лечения Плаквенил?

A: The duration of treatment depends entirely on the indication. For chronic autoimmune conditions, the medicine is often used long-term, potentially for many years. However, when used for malaria prophylaxis, the course is time-bound, involving weekly doses for several weeks around travel to an endemic area.

---

Q: Взаимодействует ли Плаквенил с витаминами или пищевыми добавками?

A: Official interaction lists do not cover all vitamins and supplements. Regulatory documents note a potential risk regarding co-administration with products containing Vitamin D, as this combination may increase the risk of hypercalcemia (high calcium levels).

---

Q: Влияет ли Плаквенил на способность водить машину?

A: Official adverse reaction profiles list dizziness and reversible visual disturbances as common side effects. The presence of these side effects may necessitate caution regarding activities like driving or operating machinery.

---

Q: Есть ли ограничения в еде при приеме Плаквенил?

A: Regulatory guidelines recommend administration of the medicine with food or milk to improve tolerability. Furthermore, the risk of serious interactions leads to a general recommendation to avoid grapefruit or grapefruit juice.

---

Q: Почему Плаквенил используют при лечении малярии?

A: Plaquenil belongs to the 4-aminoquinoline chemical family and was initially developed as an antimalarial agent. Its therapeutic action against parasitic infections is rooted in its ability to inhibit the malaria parasite.

---

Q: С чего обычно начинают лечение волчанки?

A: Studies and official information indicate that Plaquenil is shown for the treatment of Systemic Lupus Erythematosus. It is commonly utilized for long-term management across different severities of the disease due to its immunomodulatory effects.

---

Q: Как происходит метаболизм Плаквенил в организме?

A: The medicine is primarily broken down (metabolized) in the liver. Drug interactions often occur because Plaquenil affects the function of specific liver enzymes, such as CYP2D6, which are responsible for processing many other medications.

---

Q: Плаквенил — это стероид или нет?

A: No, Plaquenil is not a steroid. It is classified as an Antimalarial Agent and a Disease-Modifying Anti-Rheumatic Drug (DMARD). It works differently from corticosteroid medications.

---

Q: Показан ли Плаквенил при других заболеваниях кожи, кроме волчанки?

A: Yes, official regulatory documents list an indication for Chronic Discoid Lupus Erythematosus. This condition is a chronic inflammatory skin disease.

---

Q: Почему возникают проблемы со зрением при приеме Плаквенил?

A: While the exact mechanism of damage is not fully understood, the medicine can cause irreversible retinal damage (retinopathy). The risk of damage is associated with the duration of use and the medicine’s accumulation in eye tissues over time.

---

Q: Как часто нужно проверять зрение при длительном приеме Плаквенил?

A: Regulatory guidelines call for a baseline eye exam prior to starting therapy. Periodic monitoring, such as annual screening (including OCT and visual field testing), is then required for most patients after five years of treatment.

---

Q: Может ли Плаквенил вызывать увеличение веса?

A: Weight gain is not listed as a reported side effect in official regulatory adverse event summaries. Weight changes may occur due to the underlying disease itself or other concurrent medications, such as corticosteroids.

---

Q: Изменяется ли цвет кожи или волос при длительном приеме Плаквенил?

A: Yes, adverse event reports include the potential for darkening of the skin (hyperpigmentation) and hair loss or thinning of the hair. These effects are considered uncommon or rare.

---

Q: Что делать, если пропущена одна доза Плаквенил?

A: If a dose is missed, regulatory instructions state the rule for taking it as soon as you remember, unless it is almost time for your next dose. In that case, skip the missed dose and take the next dose at your regularly scheduled time. The instruction is to never take two doses simultaneously.

---

Q: Плаквенил отпускается по рецепту или нет?

A: Yes, Plaquenil is classified as a prescription product. It is only available through a healthcare professional's prescription.

---

Q: Что произойдет, если внезапно прекратить прием Плаквенил?

A: Official guidance warns about the risks associated with suddenly stopping this medicine. Discontinuing treatment without medical supervision may lead to a flare-up or worsening of the symptoms of the underlying chronic disease.

---

Q: Влияет ли Плаквенил на результаты анализа крови?

A: Yes, the medicine has the potential to cause serious hematological reactions (blood disorders), such as anemia or low white blood cell counts. For patients on long-term therapy, regulatory documents require periodic full blood counts for monitoring.

---

Q: Что будет, если принимать Плаквенил с грейпфрутовым соком?

A: Regulatory documents indicate that this combination is generally not recommended. Grapefruit juice may increase the concentration of the medicine in the bloodstream, which raises the risk of serious side effects, including heart rhythm abnormalities.

---

Q: Нужно ли прекращать прием Плаквенил перед хирургической операцией?

A: Guidance is typically individualized based on the procedure. The established clinical preference is often to continue the medicine during the perioperative period. If discontinuation is necessary, regulatory guidelines specify a two-week period for cessation.

---

Q: Есть ли научные данные о том, что Плаквенил помогает при COVID-19?

A: No. Major regulatory agencies do not recommend this medicine for the treatment or prevention of COVID-19. Studies demonstrated a lack of efficacy against the virus and indicated an increased risk of serious cardiac complications.

---

Q: Можно ли принимать Плаквенил, если есть проблемы со слухом?

A: Adverse event reports have associated Plaquenil with potential hearing loss, ringing in the ears (tinnitus), and vertigo. If you have pre-existing hearing concerns, official information indicates that consultation with a specialist is appropriate to assess this potential risk.

How to Store and Dispose of Plaquenil (Hydroxychloroquine Sulfate)

The storage and disposal requirements for Plaquenil tablets are regulated to maintain product quality and safety.

Storage Requirements

Component	Requirement
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Short excursions are permitted up to 30 C (86 F).
Protection	Must be kept in a tightly closed container in a dry place, protected from excessive heat.
Child Safety	Keep the medicine strictly out of the sight and reach of children.

Disposal Instructions

Unused or expired Plaquenil must not be disposed of in household trash or wastewater (e.g., flushed down a toilet or poured down a sink). The product must be disposed of in accordance with local requirements for pharmaceutical waste.